Your risk of osteoporosis (bone thinning) can be affected by breast cancer treatment and other treatments that lower your oestrogen levels. Osteoporosis is thinning of the bones so that they become more brittle. Our bones start to thin after the age of 35 or so, as part of the natural ageing process. Any cancer treatment in women that lowers oestrogen levels can increase the risk of osteoporosis. These treatments include: Tamoxifen for breast cancer usually only reduces bone density by a small amount. In postmenopausal women, aromatase inhibitors increase bone loss at an average rate of 1 to 3% per year. In young women who have had ovarian suppression followed by aromatase inhibitor therapy, bone density is lost at an average of 7 to 8% per year. Treatment with tamoxifen for 2 to 5 years before having aromatase inhibitors may slow down the rate of bone loss. Women who have had an early menopause (before the age of 45) due to cancer treatment or who have ovarian suppression therapy and aromatase inhibitors are at higher risk of bone loss. I have had multiple side effects, but a new one cropped up a few months ago - spinal osteoporosis (holes in bones) found on a routine dexascan. I am 56 years old, have been on Tamoxifen since 1/2009. I don't fit the normal profile of someone with osteoporosis so the docs think it is probably secondary to the Tamoxifen treatment - the sudden suck of estrogen out of of my body. So my internal medicine doc and oncologist talked about how to treat, and they both felt it should be treated with one of the meds on the market. I started Atelvia 2 months ago, and after last week's treatment, I started having chronic nausea and muscle cramps. The internist told me to get off of the medicine immediately. I am likely unable to take any of the meds aimed at this issue because of the side effects. Buy 100mg clomid uk Propranolol mail order Propecia kosten Clomid for men success stories Moved Permanently. The document has moved here. WebMD explains various selective estrogen receptor modulators. It is FDA-approved for the prevention and treatment of osteoporosis in. Tamoxifen has proven. The risk of osteoporosis and fracture influences the selection of adjuvant. BIG 1- 98, bone, breast cancer, endocrine therapy, tamoxifen. Topic. If you've been diagnosed with hormone-receptive breast cancer (ER/PR ) - one that depends on estrogen to grow - join the crowd: about 70% of breast cancers are hormone-receptive. A drug currently used in the EU for relief of postmenopausal issues, including osteoporosis and osteopenia, has been found to stop the growth of breast cancer cells - even in women whose cancer has proved resistant to traditional treatments. Thankfully, there are effective drugs on the market to help prevent recurrence of these types of cancers: tamoxifen (for pre-menopausal women), and aromatase inhibitors (AIs) - Arimidex, Femara, and Aromasin - for those past menopause. Once active treatment has ended, women with ER /PR cancers generally undergo long-term hormone therapy, taking either tamoxifen or an AI for 5 to 10 years. These drugs have a proven track record of working to prevent recurrence: tamoxifen has been on the market for over 30 years, the AIs for more than a decade. By depriving cancer cells of estrogen, critical to their growth. Tamoxifen is a SERM (selective estrogen-receptor modulator). It works by blocking estrogen from attaching itself to the special receptors on cancer cells. Raloxifene (Evista) belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women and to reduce risk of invasive breast cancer in postmenopausal women at high risk or with osteoporosis. SERMs were developed to reap the benefits of estrogen while avoiding the hormone's potential side effects. Raloxifene, a so-called ''designer'' estrogen, can act like estrogen on bone -- protecting its density -- but as an anti-estrogen on the lining of the uterus. In a three-year study involving some 600 postmenopausal women, raloxifene was found to increase bone density and lower LDL cholesterol, while having no stimulative effect on the uterine lining (which means that it is unlikely to cause uterine cancer). The first SERM to reach the market was tamoxifen, which blocks the stimulative effect of estrogen on breast tissue. Tamoxifen has proven valuable in preventing cancer in the second breast of women who have had cancer in one breast. Tamoxifen osteoporosis Breast cancer and osteoporosis, SERMs for Osteoporosis Raloxifene Evista - WebMD Buy cheapest generic viagra onlineWhere to buy nolvadex bodybuilding.comBuy diflucan boots Tamoxifen, sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men. Tamoxifen - Wikipedia. Bone mineral density in breast cancer patients treated with adjuvant.. Tamoxifen and Raloxifene for Lowering Breast Cancer Risk. Osteopenia and osteoporosis are prevalent in women. Tamoxifen preserves BMD in postmenopausal women; however, in premenopausal women tamoxifen. Osteoporosis is a common problem that causes your bones to become abnormally thin, weakened, and easily broken fractured. Women are at a higher risk for osteoporosis after menopause due to lower levels of estrogen, a female hormone that helps to maintain bone mass. In some women, increasing the risk of osteoporosis. • Tamoxifen Tamoxifen blocks the effects of estrogen on breast cancer cells but has the opposite effect in bones.